Summary: [14C]menaquinone-4, a therapeutic agent for osteoporosis, was administered orally to male dogs at a dose of 4 mg/kg, and the absorption, distribution, metabolism and excretion were investigated.
Introduction

Vitamin
K is an essential nutrient and a cofactor for the carboxylation of specific glutamyl residues of pro teins to y-glutamyl residues, which are vital to the blood coagulation system."2) Vitamin K dependent carboxy lase was originally observed in liver, and it has subse quently been detected in other tissues. [3] [4] [5] [6] In bone, y carboxylated osteocalcin is known to be involved in the bone remodeling system, and consequently, vitamin K deficiency may cause related diseases such as osteoporosis.7-9) Menaquinone-4 (vitamin K2) is a potent coagulation cofactor for y-carboxylase,10> with hemastatic activity comparable to phylloquinone (vitamin K1). Menaqui none-4 is now available in a soft-capsule formulation as a medication for the treatment of osteoporosis").
Its pharmacological activity has been demonstrated in human osteoblasts in vitro") and also in ovariectomized rats, the latter serving as an in vivo model for human osteoporosis. 13) The pharmacokinetic profile of menaquinone-4 in ro dents has already been reported, [14] [15] [16] [17] and that in dogs has recently been investigated using a soft-capsule for mulation following the establishment of a simple and sensitive HPLC assay method for menaquinone-4 in plasma.18) However, the metabolic fate of menaquin one-4, including its distribution into bone, the target organ of the drug, has not been determined precisely in these animals, with the exception of ovariectomized rats. 19) In this report, the absorption, distribution, metabo lism and excretion of menaquinone-4 were investigated in male dogs after oral administration of [14C]menaqui none-4. Its distribution in bone tissues was examined in particular detail since bone is the target organ of the drug. Materials and Methods
Materials
[14C]menaquinone-4 ( Fig. 1 ) was synthesized from ethyl [3 14C ]acetoacetate by Amersham (Buckingham shire, UK) according to a procedure previously described20). The specific radioactivity was 2.83 MBq/ mg and the radiochemical purity was 99% or more based upon HPLC analysis. Unlabeled menaquinone-4 was synthesized by Eisai Chemical Co., Ltd. (Ibaraki, Japan), and added to the radiolabeled compound to ob tain a specific activity of 0.72 MBq/mg prior to prepara tion of the formulation. Propyleneglycol dicaprylate (Cefsol 228®) and glycerol monooleate (MGOL-70®) were purchased from Nikko Chemicals Co., Ltd. (Tokyo, Japan). Reagents for buffer solutions were of analytical grade and other solvents were of HPLC grade (Wako Pure Chemical Industries, Ltd., Osaka, Japan).
Animals
Ten male beagle dogs were obtained from Toyo Laboratory Animals, Inc. (Shizuoka, Japan) and used at 33 months of age. Their body weights ranged from 9.0 to 13.0 kg. All animals were acclimatized for more than 1 week to a room temperature of 23 ± 1°C and a relative humidity of 55±50/ and were fed 220 g of commercial food (DS; Oriental Yeast Co., Ltd., Tokyo, Japan) and 500 ml of tap water daily throughout the study. On the 3. Preparation of [14C]menaquinone-4 dosing so lution An oily liquid formulation was prepared according to the description for a soft-capsule formulation outlined in a previous report.18) [14C]menaquinone-4 was dissolved in Cefsol 228®/MGOL-70® (40: 55, w/w) at a concen tration of 4 mg/80 mg with heating at 60°C.
Administration
[14C]menaquinone-4 solution weighed in a gelatin cap sule was orally administered to dogs at a dose of 4 mg/ kg. Thirty ml of water were given immediately after dos ing.
Measurement of radioactivity
The radioactivity was measured with a liquid scintilla tion counter (LSC-3500; Aloka, Tokyo, Japan) and quenching was corrected automatically using an exter nal standard.
6. Determination of blood, plasma and erythro cyte concentrations of radioactivity After dosing, 1.5 ml blood samples were withdrawn at specified times over a 24 hour period from four male dogs via a cephalic vein. One ml samples were collected thereafter. After a 50,ul aliquot of the blood sample was collected, the plasma was separated from the erythro cytes by centrifugation of the residual blood sample and a 50 ul aliquot of each sample was used for the measure ment of radioactivity. A 200 ul aliquot of plasma ob tained within 24 hours after a dosing was placed into an amber tube and stored at -20°C until the measurement of unchanged menaquinone-4 concentrations.
Fifty ul aliquots of blood and erythrocytes were solubi lized with 0.75 ml Soluene-350® (Packard, Groningen, Netherlands) /isopropyl alcohol (1 : 1, v/v), following which 0.25 ml of a 30% H202 solution was added to the solubilized samples for decolorization. Plasma samples (50 ul) were solubilized with 0.75 ml Soluene-350®/ isopropyl alcohol (1 : 1, v/v) before adding 6 ml of scin tillation fluid consisting of Insta-gel® (Packard) /0.5 N HCl (9: 1, v/v) to the solubilized samples.
7. Determination of menaquinone-4 in plasma Unchanged menaquinone-4 was measured as de scribed in a previous report. 18) Briefly, after adding inter nal standard (5 ug of menaquinone-6; prepared by Eisai Co., Ltd.) and 1 ml of 0.2 M phosphate buffer (pH 8) to 200 ul plasma samples, menaquinone-4 was extracted twice with 4 ml of isopropyl alcohol/n hexane (8: 92). The organic layer was then evaporated to dryness and the residue was dissolved in 200 ul of EtOH/MeOH/ H2O (50: 49: 1). The concentration of menaquinone-4 was measured with an HPLC equipped with a UV (245 nm) detector following separation of the analytes on an ODS column (Wakosil-II 5C18-HG; Wako Pure Chemi cal Industries, Ltd.). The mobile phase was EtOH/ MeOH/H20 (50: 49: 1) containing 0.1% HC1O4 at a flow rate of 1.0 ml/min. The quantification range of menaquinone-4 was 50 ng to 100 pg/ml in plasma.
Determination
of tissue concentrations of radioactivity At 1.5, 24 and 168 hours after an administration, three male dogs each were anesthetized with pentobarbital (Nembutal®; Abbott Laboratories, North Chicago, IL, USA, 25 mg/0.5 ml/kg BW), cannulated at the carotid artery and sacrificed by exsanguination. Tissues were re moved immediately and washed with saline. Bone tis sues (parietal bone, ribs, ilium and thighbone) were carefully separated from muscles and the thighbone was further divided into the metaphysis, diaphysis, cancel lous and marrow. Urine (in the bladder) and bile (in the gall bladder) were collected using a 10 ml disposable syringe. Blood samples were transferred into an amber tube and centrifuged to separate the plasma from the erythrocytes. Portions of the plasma, liver, kidneys, spleen, adrenals, adipose, bile and cancellous tissue of thighbone were stored at 20°C for the analysis of metabolites.
About 50 mg of each tissue were weighed and incubat ed with 1 ml Soluene-350® overnight at room tempera ture. Bone tissues (except bone marrow) were solubi lized with 1 ml of 5 N HCI and neutralized with 1 ml of 5 N KOH. Fifty µl aliquots of urine (from bladder) and bile (from gall bladder) were solubilized with 1 ml Sol uene-350®. After solubilization, 12 ml of scintillation fluid consisting of Insta-gel®/0.5 N HCl (9: 1, v/v) were added to each solubilized sample. Blood, plasma and erythrocyte samples were treated as described in Section 6 above.
9. Determination of radioactivity in urine and feces Four male dogs were housed in stainless steel cages af ter a dosing and urine and feces were collected daily for 7 days.
Water was mixed with feces to make total amount of 1000 g and the mixture was homogenized. About 100 mg of each homogenate were incubated with 1 ml Sol uene-350® overnight at room temperature. After solubilization, 12 ml of scintillation fluid (Insta-gel®/ 0.5 N HC1, 9 : 1, v/v) were added to each solubilized sample. One hundred µl urine samples were collected without dilution after recording the daily urine excretion volume on Days 1 and 2. On Day 3 and thereafter, urine samples were collected after dilution with water to 1000 ml. Urine samples were mixed with 6 ml of scintillation fluid (ACS-II; Amersham).
of the metabolic profile in urine, feces, bile, plasma and tissues One ml samples of plasma obtained at 1.5 and 24 hours after dosing were extracted twice with 10 ml of MeOH. Liver, kidney, spleen and adrenal samples were collected at 1.5 and 24 hours after dosing and the thighbone cancellous tissue samples at 1.5, 24 and 168 hours, and approximately 1 g of each was weighed pre cisely and extracted twice with 10 ml of MeOH follow ing homogenization (Physcotron®, NITI-ON MFG. Co., Ltd., Chiba, Japan) or sonication. Samples of adipose (about 1 g) at 1.5, 24 and 168 hours were weighed, minced and extracted twice with 10 ml of isopropyl alco hol/ n-hexane (1 : 1). Feces homogenates (around 1 g) prepared from 0-24 hour feces as described in Section 9 were extracted twice with 10 ml of MeOH. Extracted samples were evaporated under a nitrogen stream at 40°C, dissolved in a small volume of MeOH and subject ed to TLC analysis.
Two ml samples of 0-24 hour urine were lyophilized, dissolved in MeOH and subjected to TLC analysis. Bile was diluted with an equal volume of MeOH and applied to TLC analysis. The TLC conditions were as follows: The TLC plates were placed in contact with X-ray film (Ultrofilm, LKB, Bromma, Sweden) for 2 to 4 weeks to measure the radioactivity. After development (Acedol; Konica, Tokyo, Japan) and fixation (Acefix; Konica), the radioactive spots were scraped off from the plate into glass vials and mixed with 12 ml of scintilla tion fluid (ACS-II).
11. Pharmacokinetic analysis Pharmacokinetic parameters were calculated from the plasma concentrations of radioactivity and un changed menaquinone 4 using model independent analy sis as follows:
Cmax and Tmaa were determined directly from the meas ured concentrations. The AUC(o_24 hr) was obtained from the plasma concentrations for 24 hours after dosing by the trapezoidal method. The terminal half life 41/2) was estimated from the slope of the terminal phase (from 72 hours onward). The corresponding AUC(o was then calculated using the terminal t1/2.
Results
1.
Concentration of radioactivity and unchanged menaquinone-4 in blood, plasma and erythro cytes Fig. 2 shows the blood, plasma and erythrocyte con centrations of radioactivity and the plasma concentra tion of unchanged menaquinone-4 up to 24 hours after menaquinone-4 in plasma corresponded to 79.6% of the total radioactivity at 1.5 hours, and 16.3% at 10 hours. The AUC(0_24h,) for unchanged menaquinone-4 in plas ma was 8050.2 ng•hr/ml, and accounted for 31.8% of the AUC (0_24 hr) of the total radioactivity. The decrease in the concentration of radioactivity in erythrocytes was comparable to that for the plasma con centration up to 24 hours. The decrease was slower than that for the plasma concentration after 24 hours. Table I . Higher radioactivity was observed in plasma than in erythrocytes. The plasma concentration of radioactivity reached a maximum level (Cmax) of 4540.4 ng eq./ml at 1 to 2 hours after administration and thereafter decreased slowly with a terminal t1/2 of 80.1 hours. The AUC(o-24 hr) and AUC(o_-) of radioactivity in the plasma were 25342.3 and 62955.6 ng eq. • hr/ml, respectively.
The concentration of unchanged menaquinone 4 in plasma reached a maximum level (Cmax) of 3289.5 ng/ ml at 1.5 to 2 hours after administration. The concentra tion of unchanged menaquinone-4 decreased rapidly rel ative to that of radioactivity, and was below the quan tification limit (50 ng/ml) at 24 hours. The unchanged 2. Concentration of radioactivity in tissues The tissue concentrations of radioactivity at 1.5, 24 and 168 hours after administration in three male dogs are shown in Table II . The blood, plasma and erythro cyte concentrations are also presented. At 1.5 hours after an administration, the bile in gall bladder showed the highest concentration of radioactivi ty (109392.1 ng eq./ml). The liver (33164.0 ng eq./g), ileum (24024.3 ng eq./g), gall bladder (23276.7 ng eq./ g), jejunum (14165.0 ng eq./g) and spleen (12542.2 ng eq./g) showed much higher radioactivity levels than the other tissues and plasma (2994.5 ng eq. /ml) . The con centrations in the cerebrum, eyes and testes were less than one-tenth that in the plasma. At 24 hours, a majori ty of the tissues showed concentrations which were simi lar to the corresponding levels at 1.5 hours. The levels decreased in most instances by 168 hours. The concen trations in adipose and bile remained at relatively high levels at 168 hours, and the concentration in erythro cytes also remained at low levels from 24 hours on wards.
At 1.5 hours, the bone marrow (3533.4 ng eq./g) of ribs, and the cancellous tissue (2465.7 ng eq./g) and marrow of thighbone (1424.9 ng eq./g) showed concen trations comparable to that in plasma (2994.5 ng eq./ ml). The concentrations in these bone tissues decreased slowly to a level 2 to 3 times that in plasma at 24 hours. At 168 hours, the levels were 6 to 7 times higher than plasma. Other bone tissues including the parietal bone, ribs, ilium, and the metaphysis and diaphysis of the thighbone at 1.5 hours showed concentrations as low as that in the brain. The decrease in concentration from the bone tissues was relatively slow compared to that from the plasma. Table III . The cumulative excretion of radioactivity in the urine was 1.6% of the dose at 24 hours, 1.9% at 48 hours and 2.3 °% at 168 hours. The cumulative excretion of radioactivity in the feces was 65.5% of the dose at 24 hours, 75.5% at 48 hours and 78.1% at 168 hours. The total excretion of radioactivity in the urine and feces was 67.1 °% of the dose at 24 hours, 77.4% at 48 hours and 80.4% at 168 hours. A majority of the excretion was completed by 48 hours after dosing. Fig. 3 . Table IV shows the relative amounts of metabolites in plasma, urine, feces, bile, liver, kidney, spleen, adipose, adrenal and cancellous tissue of thighbone.
As shown in Fig. 3 , many metabolite fractions were observed in each sample, including previously identified metabolites, w-COOH, K acid I and K acid II (Fig. 4) .
The majority of the radioactivity in feces excreted wi thin 24 hours was in the form of unchanged menaqui none-4 (28.5%). w-COOH (11.6%) and K acid I and K acid II (4.3% in sum) were also observed. In urine ex creted up to 24 hours and bile at 1.5 and 24 hours, most of the radioactivity was present in the origin fraction on TLC.
In plasma at 1.5 hours, 61.9 °% of the radioactivity was in the form of unchanged menaquinone-4. a -000H (2.7%) and K acid I and K acid II (sum of 10.0% for the two) were also observed. The relative amount of un changed menaquinone-4 then decreased to 13.4% at 24 hours, while those of K acid I and K acid IT (29.4% in sum) and the origin fraction increased. Unchanged menaquinone 4 was the main form in the liver (56.9%), kidney (35.6%), spleen (53.3%) and adrenal (20.2%) at 1.5 hours. The metabolites w-COOH, K acid I and K acid II were present in these tissues at 1.5 hours. The rel ative amount of unchanged menaquinone 4 decreased while those of the metabolites increased in these tissues. In adipose tissue at 1.5, 24 and 168 hours, unchanged In the cancellous tissue of thighbone at 1.5 hours, 32.3% of the radioactivity was unchanged menaquin one-4. co-COOH (19.3%) and K acid I and K acid II (6.8% in sum) were also observed. The relative amount of unchanged menaquinone-4 at 24 and 168 hours in creased to 46.8 and 68.8%, respectively.
Discussion
[14C]menaquinone-4 was administered orally to male dogs at a dose of 4 mg/kg and the absorption, distribu tion, metabolism and excretion of the drug were investi gated. The dogs were fed before administration since a previous study in dogs18> suggested that feeding prior to dosing facilitated the intestinal absorption of menaqui none-4.
The plasma concentrations of both radioactivity and unchanged menaquinone-4 reached maximum levels wi thin 2 hours after oral administration (Fig. 2, Table 1 ), indicating that [14C]menaquinone-4 is rapidly absorbed from the intestine. The second plasma concentration peak at 8 hours may be due to a delay in absorption and/ or the enterohepatic circulation of [14C]menaquinone-4. The plasma concentration of radioactivity was markedly higher than the concentration in erythrocytes up to 24 hours, after which the relative concentration of radioac tivity in the erythrocyte increased (Table II) . This find ing suggests that the elimination of radioactivity from the erythrocyte is slower than from plasma, even though the concentration of radioactivity in erythrocytes at 168 hours decreased to a level about half of that at 24 hours. At 1.5 hours, the concentration ratio of unchanged menaquinone-4 to the total radioactivity in plasma was 79.6% by calculating from concentrations measured with an HPLC and a liquid scintillation counter and 61.9% by calculating from TLC analysis (Table IV) . The reason for this deviation is unclear, but may have ar isen from differences in the individual animals used and differences in the analytical method used in each experi ment. It is most likely that unchanged menaquinone-4 was the main form in plasma at 1.5 hours, and then the relative amount to the total radioactivity decreased at 10 hours (16.3% based on the calculation from each concen tration) .
By 168 hours after dosing, a major portion (78.1%) of the radioactivity administered was excreted into the feces, which contained large amounts of metabolites (Table IV) . Fairly high concentrations of radioactivity were also found in the bile at 1.5, 24 and 168 hours. These results indicate that a majority of the [14C]men aquinone-4 dosed was absorbed and then excreted mainly into the feces via the bile. At 1.5 hours after administration, the bile, liver, ile um, gall bladder, jejunum and spleen showed much higher levels of radioactivity than other tissues and plas ma (Table II) . The elimination of radioactivity from tis sues was generally slow compared to that from plasma and liver. The concentrations of radioactivity in adipose tissue were almost same from 1.5 to 168 hours (Table  II) , suggesting high levels and long-term accumulation of radioactivity in the tissue. TLC analysis conducted for the metabolic profile study revealed that most of the radioactivity in adipose tissue at 1.5, 24 and 168 hours accounted for unchanged menaquinone-4 (Table IV) . It is demonstrated from this result that excess menaqui none-4 may be stored in adipose tissue, and is thereafter released gradually. Total excretion of radioactivity into the urine and feces by 168 hours was 80.4% of the dose and the recovery of dosed radioactivity from animals was not completed (Table III) . Based on the results of tissue distribution at 168 hours, the remainder is thought to be present in the adipose and other tissues.
Although unchanged menaquinone-4 was the main form in the plasma, liver, kidney, spleen, adrenal, adi pose and cancellous tissue of thighbone at 1.5 hours, the previously identified metabolites, e)-000H, K acid I and K acid II, were also found in these tissues at 1.5 and 24 hours (Table IV) . One of the main metabolic path ways of absorbed [14C]menaquinone-4 is thought to be initial c o--oxidation to (o-000H and subsequent fl-oxida tion to K acid I and K acid II, as demonstrated previous ly in rats21 ,22) . A relatively large amount of radioactivity remained at the origin in the TLC analysis of several tis sues, particularly the bile. These results indicate that fur ther transformation of these oxidized metabolites to more polar metabolites such as glucuronides and sul fates may occur. Our previous report2l) showed that the polar metabolites in bile and urine were converted to un changed menaquinone-4 and these oxidized metabolites (as major aglycons) after hydrolysis with HCl methanol. We are now trying to identify the intact forms of these polar metabolites.
The concentrations of radioactivity in the marrow and cancellous tissue of thighbone and the marrow of ribs at 1.5 and 24 hours after administration were 1424.9 3533.4 ng eq./g (ca 3.3-8.0 x 10-6 M) and 827.2 1372.8 ng eq./g (ca 1.9-3.1 x 10-6 M), respectively (Table II) . TLC analysis for the metabolic profile study revealed that 32.3 to 46.8% of the radioactivity in the cancellous tissue at 1.5 and 24 hours corresponded to unchanged menaquinone-4 (Table IV) . These levels of menaquinone-4 are comparable to the pharmacological ly effective concentrations of menaquinone-4 (10-6 10-5 M) observed in in vitro studies on bone forma tion12). This finding suggests that menaquinone-4 dis tributes sufficiently into bone tissues after a single oral administration in dogs and that pharmacologically effec tive concentrations can be maintained by repeated ad ministration of the compound as a therapeutic agent for osteoporosis.
